Chronic Sivanar Amirtham and Suspected Mercury Toxicity
A 52-year-old woman with seropositive rheumatoid arthritis has been taking Sivanar amirtham 100 mg twice daily for 6 weeks, prescribed by a Siddha practitioner for keel vatham. She also applies a medicated kattu locally. She presents with a metallic taste, painful oral ulcers, loose stools, and reduced appetite. Examination shows gum swelling and a coarse tremor. Urine dipstick shows protein 2+, and serum creatinine is 1.6 mg/dL; her baseline three months ago was 0.8 mg/dL. She takes no NSAIDs, no herbal supplements other than the Siddha medicines, and no nephrotoxic drugs. Blood pressure is 130/80 mmHg. She asks whether she should continue the medicine because her joint pain has improved. There is no history of diabetes or hypertension.
1. What adverse effect should be suspected, and which features in the history and investigations support it?
Read the worked answer
The picture suggests chronic mercury toxicity from Sivanar amirtham, a Siddha formulation that contains mercury in processed form. Supporting features are the metallic taste, oral ulcers, gum swelling, loose stools, tremor, and a rise in serum creatinine with new proteinuria. The temporal relationship with six weeks of twice-daily dosing is important, and the absence of other nephrotoxic drugs makes an alternative cause less likely. In Siddha reasoning, the drug may have been given for vatham, but the appearance of oral ulceration and renal involvement indicates that the intended therapeutic effect has crossed into toxicity. The improvement in joint pain does not justify continuing a potentially harmful preparation. The correct judgement is to stop the suspected causative medicine, not to adjust the dose downward without assessment, and to investigate objectively.
2. Outline your immediate management, including what you would tell the patient about continuing Siddha treatment.
Read the worked answer
Stop Sivanar amirtham immediately and advise the patient not to restart it. Arrange urgent medical review for mercury toxicity: blood and urine mercury levels if available, repeat renal function, urinalysis, and assessment of oral and neurological status. Refer to a physician or poison centre for possible chelation therapy; do not attempt chelation with unproven Siddha antidotes. Report the suspected adverse drug reaction to the national pharmacovigilance system. Explain that her joint pain improvement does not outweigh the renal and systemic risks. After acute management, a qualified Siddha practitioner can consider non-metallic or safer alternatives for keel vatham, but only after renal function stabilises and with monitoring. Document the formulation, dose, duration, and batch. The key reasoning is that mercury-containing preparations require strict risk-benefit review, and new renal dysfunction is a red flag for stopping and referring.